New pill could tame rare genetic diabetes
NCT ID NCT06976658
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called dorzagliatin in 44 adults with a rare, inherited form of diabetes (GCK-MODY). The drug works by activating a key enzyme to help the body better control blood sugar. Participants will receive both the drug and a placebo at different times to see if the drug improves blood sugar levels and other measures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dorzagliatin (a drug that activates glucokinase, an enzyme that helps regulate blood sugar)
What this could lead to
If successful, this could provide a targeted oral treatment option for people with GCK-MODY, potentially improving blood sugar control without the need for insulin or other diabetes drugs.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 44 participants, so results may not apply to everyone. The drug may not significantly improve blood sugar or could have side effects. It is not a cure, as ongoing treatment would likely be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
3M, Diabetes and Endocrine Research Center
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••